New Low - Stock Screener

Market Cap	0.58M	EPS (ttm)	-1.16
P/E	-	EPS this Y	-
Forward P/E	-	EPS next Y	-
PEG	-	EPS past 5Y	-
P/S	0.34	EPS next 5Y	-
P/B	3.64	EPS Q/Q	-
Dividend	-	Sales Q/Q	-
Insider Own	3.13%	Inst Own	1.62%
Insider Trans	0.00%	Inst Trans	-
Short Float	11.57%	Earnings	-
Analyst Recom	-	Target Price	-
Avg Volume	1.12M	52W Range	0.94 - 9.38

Oct-26-23 04:05PM	China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule (GlobeNewswire)
Oct-04-23 08:30AM	China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split (GlobeNewswire)
Aug-02-23 06:03AM	China SXT Pharmaceuticals Full Year 2023 Earnings: US$0.89 loss per share (vs US$5.52 loss in FY 2022) (Simply Wall St.)
May-10-23 08:00AM	China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule (GlobeNewswire) +6.05%
Mar-29-23 09:43AM	Insiders who placed huge bets on China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) earlier this year would be disappointed with the 12% drop (Simply Wall St.)
Nov-07-22 08:00AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (GlobeNewswire)
May-18-22 12:30PM	China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split (GlobeNewswire) -27.93%
Mar-14-22 10:33PM	China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million (GlobeNewswire) -9.81%
Jan-20-22 12:30PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). (ACCESSWIRE)
10:45AM	China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment (GlobeNewswire)

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

1⋯7 8 9 10 11 12

Upgrade your FINVIZ experience